Immunovant Inc (IMVT NASDAQ) stock market data APIs
$26.6102
0.19(0.7%)
as of February 19, 2026
Try our APIs with
free plan!
Immunovant Inc Financial Data Overview
Price chart is built with
Anychart
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Prev. Close
26.6102
Open
26.8002
High
26.8631
Low
26.2282
52 wk Range
12.72-27.923
Market Cap
5 365 M
Shares Outstanding
204 M
EPS
-0.5373
Beta
0.624
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Immunovant Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Immunovant Inc data using free add-ons & libraries
Get Immunovant Inc Fundamental Data
Immunovant Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -486 751 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-18
- EPS/Forecast: -0.7269
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Immunovant Inc News
New
Indivior Pharmaceuticals to Report Q4 Earnings: What's in the Cards?
Indivior Pharmaceuticals INDV is scheduled to report fourth-quarter and full-year 2025 results on Feb. 26, before the opening bell. We expect investors to focus on the sales performance of INDV’s m...
Arcutis Biotherapeutics to Report Q4 Earnings: What's in the Cards?
Arcutis Biotherapeutics ARQT is scheduled to report fourth-quarter and full-year 2025 results on Feb. 25, after market close. We expect investors to focus on the sales performance of ARQT’s markete...
Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards?
Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus Estim...
IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus
Immunovant, Inc. (IMVT) reported third-quarter fiscal 2026 net loss of 61 cents per share, narrower than the Zacks Consensus Estimate of a loss of 72 cents. The company had reported a loss of 76 cents...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
